Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 4/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7873917 | 1.00 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| Hydrochloric Acid SCHEMBL6473967 | 0.99 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| SCHEMBL903514 | 0.89 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| Hydrochloric Acid SCHEMBL27923214 | 0.88 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| SCHEMBL7368179 | 0.86 | TACR1 (0.47) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| SCHEMBL24115492 | 0.84 | CTNNB1 (0.51) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| SCHEMBL8465002 | 0.83 | KMT2A (0.50) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| SCHEMBL3936305 | 0.83 | KMT2A (0.50) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| SCHEMBL7262986 | 0.83 | KMT2A (0.50) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 | |
| Hydrochloric Acid SCHEMBL7257593 | 0.82 | KMT2A (0.49) | SLC1A3SLC1A2SLC1A1TACR1CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
| EP-0626942-B1 | BICYCLO[2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS | BLACK JAMES FOUNDATION (GB) | 1997-04-23 | — | — | EP | disclosed |
| US-5514683-A | LIGANDS FKOR CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| EP-0626942-A1 | BICYCLO 2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS. | BLACK JAMES FOUNDATION (GB) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993016982-A1 | BICYCLO[2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | SLC1A3 2192/4885SLC1A2 3627/4885SLC1A1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.